Elicio Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Elicio Therapeutics, Inc. (ELTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $935.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $935.00K, a 31.69% increase year-over-year.
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $868.00K, a 67.89% increase year-over-year.
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $698.00K, a 122.29% increase year-over-year.
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $710.00K, a 102.86% increase year-over-year.
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.70M, a 85.74% increase from fiscal 2024.
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.45M, a 23.16% increase from fiscal 2023.
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.18M, a 103.63% increase from fiscal 2022.
- Elicio Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $579.00K, a 95.19% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $935.00K 10-Q · filed 2026-08-13 | $1.80M derived: sum of 2 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $868.00K 10-Q · filed 2026-08-13 | |||||
| 2025-12-31 | $2.70M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $698.00K 10-Q · filed 2025-11-13 | $1.41M derived: sum of 2 quarters · filed 2026-08-13 | $1.93M derived: sum of 3 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $710.00K 10-Q · filed 2026-08-13 | $1.23M derived: sum of 2 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $517.00K 10-Q · filed 2026-08-13 | |||||
| 2024-12-31 | $1.45M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $314.00K 10-Q · filed 2025-11-13 | $664.00K derived: sum of 2 quarters · filed 2025-11-13 | $988.00K derived: sum of 3 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $350.00K 10-Q · filed 2025-11-13 | $674.00K derived: sum of 2 quarters · filed 2025-11-13 | ||||
| 2024-03-31 | $324.00K 10-Q · filed 2025-11-13 | |||||
| 2023-12-31 | $1.18M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $339.00K 10-Q · filed 2024-11-13 | $618.00K derived: sum of 2 quarters · filed 2024-11-13 | $842.00K derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $279.00K 10-Q · filed 2024-11-13 | $503.00K derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $224.00K 10-Q · filed 2024-11-13 | $352.00K 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $579.00K 10-K · filed 2024-03-29 | $885.00K 10-K · filed 2023-03-17 | ||||
| 2022-09-30 | $110.00K 10-Q · filed 2023-11-13 | -$763.00K 10-Q · filed 2022-11-14 | $223.00K derived: sum of 2 quarters · filed 2023-11-13 | $380.00K derived: sum of 3 quarters · filed 2023-11-13 | $2.40M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $113.00K 10-Q · filed 2023-11-13 | $1.40M 10-Q · filed 2022-08-15 | $270.00K derived: sum of 2 quarters · filed 2023-11-13 | $2.29M derived: sum of 3 quarters · filed 2023-11-13 | $4.48M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-03-31 | $157.00K 10-Q · filed 2023-11-13 | $31.00K 10-Q · filed 2022-05-16 | $2.18M derived: sum of 2 quarters · filed 2023-11-13 | $4.36M derived: sum of 3 quarters · filed 2023-11-13 | $7.08M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2021-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $4.21M derived: sum of 2 quarters · filed 2023-03-17 | $6.92M derived: sum of 3 quarters · filed 2023-03-17 | $12.04M 10-K · filed 2023-03-17 | ||
| 2021-09-30 | $2.18M 10-Q · filed 2022-11-14 | $4.90M derived: sum of 2 quarters · filed 2022-11-14 | $10.02M 10-Q · filed 2021-11-12 | $11.18M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $2.72M 10-Q · filed 2022-11-14 | $7.83M derived: sum of 2 quarters · filed 2022-11-14 | $9.00M derived: sum of 3 quarters · filed 2022-11-14 | $10.62M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $5.12M 10-Q · filed 2022-11-14 | $6.28M derived: sum of 2 quarters · filed 2022-11-14 | $7.91M derived: sum of 3 quarters · filed 2022-11-14 | $9.00M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2020-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $2.79M derived: sum of 2 quarters · filed 2022-03-30 | $3.88M derived: sum of 3 quarters · filed 2022-03-30 | $4.72M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $1.63M 10-Q · filed 2021-11-12 | $2.72M derived: sum of 2 quarters · filed 2021-11-12 | $3.55M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $1.09M 10-Q · filed 2021-08-12 | $1.93M derived: sum of 2 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $832.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |